# A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

> **NCT06769152** · PHASE2 · RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 190 (estimated)

## Conditions studied

- Cervical Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** HLX43

## Key facts

- **NCT ID:** NCT06769152
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-05
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769152, "A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06769152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*